MFS
PRTK

MSI Financial Services’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

MSI Financial Services’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-8
Closed – – 3989
2015
Q3 		$0 Buy
+8
New +$199 ﹤0.01% 3408

Other funds holding PRTK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BBHC
Brown Brothers Harriman & Co New York $18.6B AUM 15.81% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MSI Financial Services's PRTK Position: Q4 2015 in Review

MSI Financial Services sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q4 2015, closing a stake of 8 shares.

MSI Financial Services first reported a position in PRTK in Q3 2015 and held it in 1 quarter. The position peaked at $0 in Q3 2015. 62 funds tracked by Wall St. Rank hold PRTK as of Q4 2015.

  • MSI Financial Services reported no remaining Paratek Pharmaceuticals, Inc. position as of Q4 2015 after selling out during the quarter.
  • MSI Financial Services sold 8 Paratek Pharmaceuticals, Inc. shares in Q4 2015.
  • MSI Financial Services first reported a position in Paratek Pharmaceuticals, Inc. in Q3 2015 and held it in 1 quarter.
  • MSI Financial Services's Paratek Pharmaceuticals, Inc. position peaked at $0 in Q3 2015.
  • 62 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q4 2015.

Based on MSI Financial Services's 13F filing for Q4 2015, filed 4 Feb 2016.